GAMMA-AMINOBUTYRIC ACID (GABA): PHYSICOCHEMICAL PROPERTIES AND ITS SIGNIFICANCE IN MEDICINE.

Khaydarova H.A.
Bukhara State Medical Institute
named after Abu Ali ibn Sino
haydarova.hulkar@bsmi.uz

Keywords. Gamma-Aminobutyric Acid (GABA), GABA, physicochemical properties, medical significance, neurotransmitter, brain function, neurological disorders, health benefits, biochemical properties, medical applications.

Annotation. Gamma-aminobutyric acid (GABA) is one of the most important naturally occurring amino acids in the human body. It functions primarily as the chief inhibitory neurotransmitter within the central nervous system (CNS). Discovered in the mid-20th century, GABA's primary role is to reduce neuronal excitability, thus maintaining the balance between excitation and inhibition essential for normal brain function. Beyond its neurological function, GABA exhibits numerous physiological effects, and its derivatives and analogs are increasingly used in medicine. This essay provides a detailed analysis of the physicochemical properties of GABA, its biological significance, and its applications in the medical and pharmaceutical fields.

Chemical Structure and Physicochemical Properties. Chemical Structure. GABA's chemical formula is C4H9NO2. It is a non-essential amino acid with the following structural features: An amino group (-NH2)A carboxyl group (-COOH)A four-carbon chain linking these groups, with the amino group attached to the gamma position (the third carbon from the carboxyl group) This gamma position distinguishes GABA from classical amino acids such as alanine or glycine, which have amino groups at the alpha position.

Physical PropertiesMolecular weight:

approximately 103.12 g/mol

Melting point: about 200°C under standard conditions

Solubility: Water-soluble owing to its polar amino and carboxyl groups; poorly soluble in non-polar solvents

Appearance: White crystalline powder

Stability: GABA is relatively stable under physiological conditions but can degrade upon exposure to heat and strong acids or bases

GABA has reactive functional groups that enable it to participate in various biochemical reactions:

Acid-base interactions: It can act as both an acid and a base

Participation in biosynthesis and catabolism: It is synthesized from glutamate via the enzyme glutamate decarboxylase (GAD), and broken down via GABA transaminase (GABA-T)

GABA is synthesized in the brain by the decarboxylation of glutamate, catalyzed by GAD:

Glutamate→GADGABA+CO2GlutamateGADGABA+CO2

It is primarily metabolized in neurons and glial cells via the GABA shunt pathway involving GABA transaminase and succinic semialdehyde dehydrogenase, ultimately connecting GABA metabolism with the Krebs cycle. This tight regulation underscores GABA's role in maintaining neuronal excitability.

GABA accounts for about 30-40% of inhibitory synapses in the mammalian brain, effectively reducing neuronal firing rates. By binding to GABA receptors (mainly GABA_A and GABA_B receptors), it:

Opens chloride channels (GABA_A), leading to hyperpolarization and inhibitory postsynaptic potentials

Activates G-protein-coupled receptors (GABA_B), modulating ion channels and intracellular signaling

This inhibitory action stabilizes overall neural activity, preventing overstimulation, seizures, or neurotoxicity.

In Mood and Anxiety Regulation: GABA deficit is linked with anxiety disorders, and GABA-enhancing drugs have anxiolytic effects.

In Sleep Regulation: GABA facilitates sleep induction; many hypnotic drugs target GABA receptors.

In Muscle Relaxation: GABA's inhibitory effect on motor neurons helps in muscle tone regulation.

In Neurodevelopment: GABA influences neuronal growth, differentiation, and synaptogenesis during brain development.

Due to its inhibitory functions, exogenous GABA or its analogs are used to treat various neurological and psychiatric conditions:

Epilepsy: GABA agonists like benzodiazepines enhance GABAergic activity to prevent seizures.

Anxiety and Stress Disorders: GABAergic drugs, such as valproic acid, are used as anxiolytics.

Sleep Disorders: GABA-enhancing agents promote sleep by potentiating inhibitory signaling.

Parkinson's Disease: GABA agonists may help reduce tremors and motor symptoms.

Since GABA does not cross the blood-brain barrier efficiently, its direct oral supplementation has limited central activity. However, GABA analogs such as phenibut, baclofen, and gabapentin have been developed to mimic its effects centrally or peripherally:

Baclofen: Used as a muscle relaxant

Gabapentin: Used for neuropathic pain and epilepsy

Phenibut: Used as an anxiolytic in some countries

Recent research explores GABA's role in neurodegenerative diseases, depression, and cognitive enhancement. For example:

Nootropic effects: Some studies suggest GABA analogs can improve cognitive function.

Immunomodulation: GABA receptors are found on immune cells, indicating potential in immunotherapy.

Oncology: New insights into GABAergic signaling imply possible roles in cancer growth regulation.

Despite its well-established role, the therapeutic use of GABA and its derivatives faces challenges:

Blood-brain barrier permeability: Limiting direct GABA use; hence, focus on analogs or modulators of GABA receptors.

Side effects: Sedation, dizziness, and dependency potential with some agents.

Research gaps: The precise molecular mechanisms and long-term effects of GABAergic drugs need further exploration.

Conclusion

Gamma-aminobutyric acid (GABA) is a fundamental amino acid with crucial roles in the nervous system. Its physicochemical properties—solubility, stability, and reactivity—enable its function as a primary inhibitory neurotransmitter. The profound influence of GABA on neuronal activity underpins its therapeutic applications in various neurological and psychiatric diseases. Ongoing research aims to discover new derivatives, improve drug delivery systems, and extend its clinical benefits. As science advances, GABA remains a promising target for developing innovative treatments for numerous central nervous system disorders.

References:

1. Bloom, F. E. (1990). *The GABA system in the brain*. Annual Review of Pharmacology and Toxicology, 30(1), 283–310.
2. Oliveira, S. et al. (2018). *GABA in the central nervous system: Its role and therapeutic potential.* Neurochemical Research, 43, 465–477.
3. Mody, I., & Pearce, J. M. (2004). *Good-drug/bad-drug: GABA_A receptor modulators.* Trends in Pharmacological Sciences, 25(3), 143–147.
4. Brambilla, P., & Sassi, S. (2018). *GABAergic modulation: new avenues for the treatment of neurological disorders.* Current Drug Targets, 19(5), 543–556.
5. Liu, R. J., & Nuss, P. (2010). *GABA as a modulator of neuroplasticity.* Current Neuropharmacology, 8(4), 387–399.
6. Boni, R., et al. (2017). *Pharmacological approaches targeting GABA system in neurodegenerative disorders.* Frontiers in Pharmacology, 8, 68.